Higher tariffs imposed by the U.S. on certain pharmaceutical imports from India are unlikely to impact the country’s competitive edge in the American market, according to industry experts. India remains a dominant player in the U.S. pharmaceutical sector, supplying around 40% of generic drugs. Factors such as cost-efficient manufacturing, a skilled workforce, and regulatory compliance continue to support India’s strong market presence.
While the Biden administration has increased tariffs on some Chinese pharmaceutical ingredients, India is seen as a reliable alternative for drug production. The Indian pharmaceutical industry has also been expanding its manufacturing capabilities, reducing dependence on Chinese raw materials. This shift enhances supply chain resilience and ensures steady exports to the U.S.
Industry leaders believe that India’s ability to produce affordable, high-quality medicines will help it withstand tariff changes. Additionally, ongoing investments in research and development (R&D), innovation, and adherence to U.S. FDA standards reinforce India’s position as a preferred supplier.
Despite potential short-term cost pressures, Indian pharmaceutical firms are expected to remain competitive by leveraging economies of scale and focusing on high-value drug formulations. The long-term outlook remains positive, driven by global demand for affordable medicines and strong bilateral trade relations.
#IndiaPharma #USPharmaMarket #GenericDrugs #PharmaExports #TradeRelations #HealthcareIndustry #MedTech #Tariffs #PharmaManufacturing #SupplyChain #AffordableMedicine #PharmaInnovation #DrugSupply #FDACertified #HealthTech #GlobalPharma #PharmaceuticalIndustry #dseidehealthcarenetwork
Source: Financial Express
While the Biden administration has increased tariffs on some Chinese pharmaceutical ingredients, India is seen as a reliable alternative for drug production. The Indian pharmaceutical industry has also been expanding its manufacturing capabilities, reducing dependence on Chinese raw materials. This shift enhances supply chain resilience and ensures steady exports to the U.S.
Industry leaders believe that India’s ability to produce affordable, high-quality medicines will help it withstand tariff changes. Additionally, ongoing investments in research and development (R&D), innovation, and adherence to U.S. FDA standards reinforce India’s position as a preferred supplier.
Despite potential short-term cost pressures, Indian pharmaceutical firms are expected to remain competitive by leveraging economies of scale and focusing on high-value drug formulations. The long-term outlook remains positive, driven by global demand for affordable medicines and strong bilateral trade relations.
#IndiaPharma #USPharmaMarket #GenericDrugs #PharmaExports #TradeRelations #HealthcareIndustry #MedTech #Tariffs #PharmaManufacturing #SupplyChain #AffordableMedicine #PharmaInnovation #DrugSupply #FDACertified #HealthTech #GlobalPharma #PharmaceuticalIndustry #dseidehealthcarenetwork
Source: Financial Express
Higher tariffs imposed by the U.S. on certain pharmaceutical imports from India are unlikely to impact the country’s competitive edge in the American market, according to industry experts. India remains a dominant player in the U.S. pharmaceutical sector, supplying around 40% of generic drugs. Factors such as cost-efficient manufacturing, a skilled workforce, and regulatory compliance continue to support India’s strong market presence.
While the Biden administration has increased tariffs on some Chinese pharmaceutical ingredients, India is seen as a reliable alternative for drug production. The Indian pharmaceutical industry has also been expanding its manufacturing capabilities, reducing dependence on Chinese raw materials. This shift enhances supply chain resilience and ensures steady exports to the U.S.
Industry leaders believe that India’s ability to produce affordable, high-quality medicines will help it withstand tariff changes. Additionally, ongoing investments in research and development (R&D), innovation, and adherence to U.S. FDA standards reinforce India’s position as a preferred supplier.
Despite potential short-term cost pressures, Indian pharmaceutical firms are expected to remain competitive by leveraging economies of scale and focusing on high-value drug formulations. The long-term outlook remains positive, driven by global demand for affordable medicines and strong bilateral trade relations.
#IndiaPharma #USPharmaMarket #GenericDrugs #PharmaExports #TradeRelations #HealthcareIndustry #MedTech #Tariffs #PharmaManufacturing #SupplyChain #AffordableMedicine #PharmaInnovation #DrugSupply #FDACertified #HealthTech #GlobalPharma #PharmaceuticalIndustry #dseidehealthcarenetwork
Source: Financial Express
